The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis

References

• Kabra SK, Jain Y, Singhal T, et al. Dengue hemorrhagic fever: clinical manifestations and management. Indian J Pediatr. 1999;66(1):93–101.
   PubMedGoogle Scholar
• Kalayanarooj S. Clinical manifestations and management of dengue/DHF/DSS. Trop Med Health. 2011;39(4 Suppl):83–87.
   PubMedGoogle Scholar
• Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480–496.
   PubMed Web of Science ®Google Scholar
• Dietz V, Gubler DJ, Ortiz S, et al. The 1986 dengue and dengue hemorrhagic fever epidemic in Puerto Rico: epidemiologic and clinical observations. P R Health Sci J. 1996;15(3):201–210.
   PubMedGoogle Scholar
• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and control of dengue and dengue haemorrhagic fever: comprehensive guidelines. SEARO technical publication series. World Health Organization; 2011.
   Google Scholar
• Aedes albopictus (Skuse) in Singapore City, Chan YC, Ho BC, Chan KL, et al. 5. Observations in relation to dengue haemorrhagic fever. Bull World Health Organ. 1971;44(5):651–657.
   PubMed Web of Science ®Google Scholar
• Walker T, Johnson PH, Moreira LA, et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature. 2011;476(7361):450–453.
   PubMed Web of Science ®Google Scholar
• Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol. 2008;22(3):203–221.
   PubMed Web of Science ®Google Scholar
• Horstick O, Runge-Ranzinger S, Nathan MB, et al. Dengue vector-control services: how do they work? A systematic literature review and country case studies. Trans R Soc Trop Med Hyg. 2010;104(6):379–386.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro S. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet. 2014; 384:1358-1365.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 2012;380(9853):1559–1567.
   PubMed Web of Science ®Google Scholar
• Guy B, Lang J, Saville M, et al. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67(1):387–404.
   PubMed Web of Science ®Google Scholar
• Pyke AT, Moore PR, Taylor CT, et al. Highly divergent dengue virus type 1 genotype sets a new distance record. Scientific …. 2016;6:22356.
   PubMed Web of Science ®Google Scholar
• Ioos S, Mallet H-P, Leparc Goffart I, et al. Current Zika virus epidemiology and recent epidemics. Med Mal Infect. 2014;44(7):302–307.
   PubMed Web of Science ®Google Scholar
• Santos Dos T, Rodriguez A, Almiron M, et al. Zika Virus and the Guillain–Barré Syndrome — Case Series from Seven Countries. N Engl J Med. 2016;375:1598–1601.
   PubMedGoogle Scholar
• Arias A, Torres-Tobar L, Hernández G, et al. Guillain-Barré syndrome in patients with a recent history of Zika in Cúcuta, Colombia: A descriptive case series of 19 patients from December 2015 to March 2016. J Crit Care. 2016;37:19–23.
   PubMedGoogle Scholar
• Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–958.
   PubMed Web of Science ®Google Scholar
• Štrafela P, Vizjak A, Mraz J, et al. Zika virus-associated micrencephaly: a thorough description of neuropathologic findings in the fetal central nervous system. Arch Pathol Lab Med. 2016;arpa.2016–0341–SA.
   PubMedGoogle Scholar
• Halstead SB, O’Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265(5596):739–741.
   PubMed Web of Science ®Google Scholar
• Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol. 1994;68(6):3499–3504.
   PubMed Web of Science ®Google Scholar
• Sauter P, Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 2009;11(4):443–451.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Anderson LJ, Marcoux L, et al. Antibody-mediated enhancement of respiratory syncytial virus infection in two monocyte/macrophage cell lines. J Infect Dis. 1989;160(5):777–782.
   PubMed Web of Science ®Google Scholar
• Takada A, Feldmann H, Ksiazek TG, et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539–7544.
   PubMed Web of Science ®Google Scholar
• Willey S, Aasa-Chapman MMI, O’Farrell S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology. 2011;8(1):16.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102–1108.
   PubMed Web of Science ®Google Scholar
• Chan KR, Ong EZ, Tan HC, et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci U S A. 2014;111(7):2722–2727.
   PubMed Web of Science ®Google Scholar
• Rodrigo WWSI, Jin X, Blackley SD, et al. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol. 2006;80(20):10128–10138.
   PubMed Web of Science ®Google Scholar
• Chawla T, Chan KR, Zhang SL, et al. Dengue virus neutralization in cells expressing Fc gamma receptors. PLoS ONE. 2013;8(5):e65231.
   PubMed Web of Science ®Google Scholar
• Ng JKW, Zhang SL, Tan HC, et al. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog. 2014;10(4):e1004031.
   PubMed Web of Science ®Google Scholar
• Chan KR, Wang X, Saron WAA, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol. 2016;1:16164.
   Web of Science ®Google Scholar
• Perera R, Kuhn RJ. Structural proteomics of dengue virus. Curr Opin Microbiol. 2008;11(4):369–377.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol. 2005;3(1):13–22.
   PubMed Web of Science ®Google Scholar
• Stadler K, Allison SL, Schalich J, et al. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71(11):8475–8481.
   PubMed Web of Science ®Google Scholar
• Li L, Lok SM, Yu I-M, et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008;319(5871):1830–1834.
   PubMed Web of Science ®Google Scholar
• Junjhon J, Edwards TJ, Utaipat U, et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol. 2010;84(16):8353–8358.
   PubMed Web of Science ®Google Scholar
• Richter MKS, Da Silva Voorham JM, Torres Pedraza S, et al. Immature dengue virus is infectious in human immature dendritic cells via interaction with the receptor molecule DC-SIGN. PLoS ONE. 2014;9(6):e98785.
   Google Scholar
• Modis Y, Ogata S, Clements D, et al. A ligand-binding pocket in the dengue virus envelope glycoprotein. Pnas. 2003;100(12):6986–6991.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109(19):7439–7444.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Beltramello M, Messer WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5(6):e1188.
   PubMed Web of Science ®Google Scholar
• Smith SA, De Alwis AR, Kose N, et al. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol. 2014;88(21):12233–12241.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Austin SK, Fremont DH, et al. The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology. 2013;439(1):57–64.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Donaldson EF, De Alwis R, et al. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010;6(3):e1000821.
   PubMed Web of Science ®Google Scholar
• Serafin IL, Aaskov JG. Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch Virol. 2001;146(12):2469–2479.
   PubMed Web of Science ®Google Scholar
• Matsui K, Gromowski GD, Li L, et al. Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III. J Gen Virol. 2010;91(Pt 9):2249–2253.
   PubMed Web of Science ®Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15(3):312–317.
   PubMed Web of Science ®Google Scholar
• Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015;162(3):493–504.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Ibarra KD, Ng T-S, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349(6243):88–91.
   PubMed Web of Science ®Google Scholar
• Crill WD, Chang G-J-J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78(24):13975–13986.
   PubMed Web of Science ®Google Scholar
• Smith SA, De Alwis AR, Kose N, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013;4(6):e00873–13.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett ADT. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007;366(2):349–360.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81(23):12816–12826.
   PubMed Web of Science ®Google Scholar
• Shrestha B, Brien JD, Sukupolvi-Petty S, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010;6(4):e1000823.
   PubMed Web of Science ®Google Scholar
• Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4(139):139ra83–139ra83.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103–113.
   PubMed Web of Science ®Google Scholar
• Williams KL, Wahala WMPB, Orozco S, et al. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012;429(1):12–20.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Silva AM de. The human antibody response to dengue virus infection. Viruses. 2011;3(12):2374–2395.
   PubMed Web of Science ®Google Scholar
• Mandel B. Neutralization of poliovirus: a hypothesis to explain the mechanism and the one-hit character of the neutralization reaction. Virology. 1976;69(2):500–510.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Pierson TC, Fremont DH. The structural immunology of antibody protection against West Nile virus. Immunol Rev. 2008;225(1):212–225.
   PubMed Web of Science ®Google Scholar
• Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology. 2011;411(2):306–315.
   PubMed Web of Science ®Google Scholar
• Putnak JR, La Barrera De R, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg. 2008;79(1):115–122.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Hombach J, Barrett ADT. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21(2):123–132.
   PubMed Web of Science ®Google Scholar
• Kou Z, Quinn M, Chen H, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2008;80(1):134–146.
   PubMed Web of Science ®Google Scholar
• Pham AM, Langlois RA, TenOever BR. Replication in cells of hematopoietic origin is necessary for dengue virus dissemination. PLoS Pathog. 2012;8(1):e1002465.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Chau TNB, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis. 2007;196(3):416–424.
   PubMed Web of Science ®Google Scholar
• Perret C, Chanthavanich P, Pengsaa K, et al. Dengue infection during pregnancy and transplacental antibody transfer in Thai mothers. J Infect. 2005;51(4):287–293.
   PubMed Web of Science ®Google Scholar
• Ventura AK, Ehrenkranz NJ, Rosenthal D. Placental passage of antibodies to dengue virus in persons living in a region of hyperendemic dengue virus infection. J Infect Dis. 1975;131(Suppl):S62–8.
   Google Scholar
• Maeda M, Van SCHIE RCAA, Yüksel B, et al. Differential expression of Fc receptors for IgG by monocytes and granulocytes from neonates and adults. Clin Exp Immunol. 1996;103(2):343–347.
   PubMed Web of Science ®Google Scholar
• Manokaran G, Finol E, Wang C, et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science. 2015;350(6257):217–221.
   PubMed Web of Science ®Google Scholar
• Pozo-Aguilar JO, Monroy-Martínez V, Díaz D, et al. Evaluation of host and viral factors associated with severe dengue based on the 2009 WHO classification. Parasit Vectors. 2014;7(1):243.
   PubMed Web of Science ®Google Scholar
• Duangchinda T, Dejnirattisai W, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107(39):16922–16927.
   PubMed Web of Science ®Google Scholar
• Chan KR, Ong EZ, Ooi EE. Therapeutic antibodies as a treatment option for dengue fever. Expert Rev Anti Infect Ther. 2013;11(11):1147–1157.
   PubMed Web of Science ®Google Scholar
• Kwissa M, Nakaya HI, Onlamoon N, et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe. 2014;16(1):115–127.
   PubMed Web of Science ®Google Scholar
• Wong KL, Chen W, Balakrishnan T, et al. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. PLoS ONE. 2012;7(5):e36435.
   Google Scholar
• Van De Winkel JG, Anderson CL. Biology of human immunoglobulin G Fc receptors. J Leukoc Biol. 1991;49(5):511–524.
   PubMed Web of Science ®Google Scholar
• Rodrigo WWSI, Block OKT, Lane C, et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology. 2009;394(2):175–182.
   PubMed Web of Science ®Google Scholar
• Chan KR, Zhang SL-X, Tan HC, et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A. 2011;108(30):12479–12484.
   PubMed Web of Science ®Google Scholar
• Wu RSL, Chan KR, Tan HC, et al. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antiviral research. 2012;96(3):340–343.
   PubMed Web of Science ®Google Scholar
• Boonnak K, Slike BM, Donofrio GC, et al. Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol. 2013;190(11):5659–5665.
   PubMed Web of Science ®Google Scholar
• Amigorena S, Bonnerot C. Fc receptor signaling and trafficking: a connection for antigen processing. Immunol Rev. 1999;172:279–284.
   PubMed Web of Science ®Google Scholar
• Isakov N. Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. J Leukoc Biol. 1997;61(1):6–16.
   PubMed Web of Science ®Google Scholar
• Lowell CA. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb Perspect Biol. 2011;3(3):a002352–a002352.
   PubMed Web of Science ®Google Scholar
• Ibarrola I, Vossebeld PJ, Homburg CH, et al. Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIa. Biochim Biophys Acta. 1997;1357(3):348–358.
   PubMed Web of Science ®Google Scholar
• Ezumi Y, Shindoh K, Tsuji M, et al. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med. 1998;188(2):267–276.
   PubMed Web of Science ®Google Scholar
• Ghazizadeh S, Bolen JB, Fleit HB. Physical and functional association of Src-related protein tyrosine kinases with Fc gamma RII in monocytic THP-1 cells. J Biol Chem. 1994;269(12):8878–8884.
   PubMed Web of Science ®Google Scholar
• Melendez AJ, Harnett MM, Allen JM. FcγRI activation of phospholipase Cγ1 and protein kinase C in dibutyryl cAMP-differentiated U937 cells is dependent solely on the tyrosine-kinase activated form of phosphatidylinositol-3-kinase. Immunology. 1999;98(1):1–8.
   PubMed Web of Science ®Google Scholar
• Rankin BM, Yocum SA, Mittler RS, et al. Stimulation of tyrosine phosphorylation and calcium mobilization by Fc gamma receptor cross-linking. Regulation by the phosphotyrosine phosphatase CD45. J Immunol. 1993;150(2):605–616.
   PubMed Web of Science ®Google Scholar
• Ayala-Nunez NV, Hoornweg TE, Van De Pol DPI, et al. How antibodies alter the cell entry pathway of dengue virus particles in macrophages. Sci Rep. 2016;6:28768.
   PubMed Web of Science ®Google Scholar
• Mady BJ, Erbe DV, Kurane I, et al. Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol. 1991;147(9):3139–3144.
   PubMed Web of Science ®Google Scholar
• Chotiwan N, Roehrig JT, Schlesinger JJ, et al. Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection. Virology. 2014;456-457:238–246.
   PubMed Web of Science ®Google Scholar
• Huang Z-Y, Hunter S, Kim M-K, et al. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukoc Biol. 2003;73(6):823–829.
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Banerjee D, Connolly J, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007;204(6):1359–1369.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10(10):712–722.
   PubMed Web of Science ®Google Scholar
• Yang KD, Yeh WT, Yang MY, et al. Antibody-dependent enhancement of heterotypic dengue infections involved in suppression of IFNgamma production. J Med Virol. 2001;63(2):150–157.
   PubMed Web of Science ®Google Scholar
• Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol. 2007;88(Pt 2):365–375.
   PubMed Web of Science ®Google Scholar
• Tsai -T-T, Chuang Y-J, Lin Y-S, et al. Antibody-dependent enhancement infection facilitates dengue virus-regulated signaling of IL-10 production in monocytes. PLoS Negl Trop Dis. 2014;8(11):e3320.
   Google Scholar
• Ubol S, Phuklia W, Kalayanarooj S, et al. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis. 2010;201(6):923–935.
   PubMed Web of Science ®Google Scholar
• Kou Z, Lim JYH, Beltramello M, et al. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology. 2011;410(1):240–247.
   PubMed Web of Science ®Google Scholar
• Flipse J, Diosa-Toro MA, Hoornweg TE, et al. Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses. Sci Rep. 2016;6:29201.
   PubMed Web of Science ®Google Scholar
• Moi ML, Lim C-K, Chua KB, et al. Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis. 2012;6(2):e1536.
   Google Scholar
• Tridandapani S, Siefker K, Teillaud J-L, et al. Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J Biol Chem. 2002;277(7):5082–5089.
   PubMed Web of Science ®Google Scholar
• García G, Sierra B, Pérez AB, et al. Asymptomatic dengue infection in a cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg. 2010;82(6):1153–1156.
   PubMed Web of Science ®Google Scholar
• Noecker CA, Amaya-Larios IY, Galeana-Hernández M, et al. Contrasting associations of polymorphisms in FcγRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. Acta Trop. 2014;138:15–22.
   PubMed Web of Science ®Google Scholar
• Osborne JM, Chacko GW, Brandt JT, et al. Ethnic variation in frequency of an allelic polymorphism of human Fc gamma RIIA determined with allele specific oligonucleotide probes. J Immunol Methods. 1994;173(2):207–217.
   PubMed Web of Science ®Google Scholar
• Chan KR, Ong EZ, Mok DZ, et al. Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther. 2015;13(11):1351–1360.
   PubMed Web of Science ®Google Scholar
• Sittisombut N, Maneekarn N, Kanjanahaluethai A, et al. Lack of augmenting effect of interferon-gamma on dengue virus multiplication in human peripheral blood monocytes. J Med Virol. 1995;45(1):43–49.
   PubMed Web of Science ®Google Scholar
• Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166(1):531–537.
   PubMed Web of Science ®Google Scholar
• Tridandapani S, Wardrop R, Baran CP, et al. TGF-beta 1 suppresses [correction of supresses] myeloid Fc gamma receptor function by regulating the expression and function of the common gamma-subunit. J Immunol. 2003;170(9):4572–4577.
   PubMed Web of Science ®Google Scholar
• Moxey-Mims MM, Frank MM, Lin EY, et al. Increased expression of Fc gamma RI on isolated PMN from individuals of African descent. Clin Immunol Immunopathol. 1993;69(1):117–121.
   PubMedGoogle Scholar
• Seidler S, Zimmermann HW, Bartneck M, et al. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol. 2010;11(1):30.
   PubMed Web of Science ®Google Scholar